CN1691946A - 他克莫司(FK506)衍生物联合β2－激动剂用于治疗哮喘的用途 - Google Patents

他克莫司(FK506)衍生物联合β2－激动剂用于治疗哮喘的用途 Download PDF

Info

Publication number
CN1691946A
CN1691946A CNA2003801007188A CN200380100718A CN1691946A CN 1691946 A CN1691946 A CN 1691946A CN A2003801007188 A CNA2003801007188 A CN A2003801007188A CN 200380100718 A CN200380100718 A CN 200380100718A CN 1691946 A CN1691946 A CN 1691946A
Authority
CN
China
Prior art keywords
group
agonist
acute
treatment
chronic asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801007188A
Other languages
English (en)
Chinese (zh)
Inventor
平山良孝
森下佳彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1691946A publication Critical patent/CN1691946A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2003801007188A 2002-11-08 2003-11-04 他克莫司(FK506)衍生物联合β2－激动剂用于治疗哮喘的用途 Pending CN1691946A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002952559 2002-11-08
AU2002952559A AU2002952559A0 (en) 2002-11-08 2002-11-08 New use

Publications (1)

Publication Number Publication Date
CN1691946A true CN1691946A (zh) 2005-11-02

Family

ID=28795949

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801007188A Pending CN1691946A (zh) 2002-11-08 2003-11-04 他克莫司(FK506)衍生物联合β2－激动剂用于治疗哮喘的用途

Country Status (8)

Country Link
US (1) US20060035918A1 (https=)
EP (1) EP1558249A1 (https=)
JP (1) JP2006506413A (https=)
KR (1) KR20050071491A (https=)
CN (1) CN1691946A (https=)
AU (1) AU2002952559A0 (https=)
CA (1) CA2499719A1 (https=)
WO (1) WO2004041278A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113939519A (zh) * 2018-12-11 2022-01-14 莫尔根生物有限公司 促进毛发生长的新化合物及包含它们的组合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101410122A (zh) * 2006-03-14 2009-04-15 厚生药业股份有限公司 治疗过敏性疾病的方法及组合物
EP3094324A4 (en) 2014-01-13 2017-02-22 Amplyx Pharmaceuticals, Inc. Antifungal compounds
KR101632042B1 (ko) 2014-06-30 2016-06-21 주식회사 인트론바이오테크놀로지 Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도
WO2020122609A1 (ko) * 2018-12-11 2020-06-18 주식회사 인트론바이오테크놀로지 신규 화합물 및 이를 포함하는 신경계 질환 치료용 약학적 조성물
KR102134782B1 (ko) * 2018-12-11 2020-07-17 주식회사 인트론바이오테크놀로지 신규 화합물 및 이를 포함하는 신경계 질환 치료용 약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64214B1 (en) * 1989-06-06 1995-07-26 Fujisawa Pharmaceutical Co Macrolides for the treatment of reversible obstructive airways diseases
US5519049A (en) * 1989-06-06 1996-05-21 Fisons Plc Macrolides for the treatment of reversible obstructive airways diseases
CN1137680C (zh) * 1995-09-19 2004-02-11 藤泽药品工业株式会社 气雾剂组合物
US5990097A (en) * 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113939519A (zh) * 2018-12-11 2022-01-14 莫尔根生物有限公司 促进毛发生长的新化合物及包含它们的组合物

Also Published As

Publication number Publication date
WO2004041278A1 (en) 2004-05-21
AU2002952559A0 (en) 2002-11-21
EP1558249A1 (en) 2005-08-03
KR20050071491A (ko) 2005-07-07
JP2006506413A (ja) 2006-02-23
US20060035918A1 (en) 2006-02-16
CA2499719A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
CN1137680C (zh) 气雾剂组合物
CN1108152C (zh) 口服雷怕霉素配方
CN1289086C (zh) 抗疟治疗药物的新用途
CN1638729A (zh) 含有β2－激动剂的溶液的加压计量吸入器
US20230372275A1 (en) Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases
AU2019378161B2 (en) Crystalline forms of a substituted imidazopyridine compound and use thereof as P2x3 modulator
EP2902025B1 (en) Therapeutic agent for dyslipidemia
HK1043064A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
JP2020114813A (ja) フェノール性ｔｒｐｖ１アゴニストのプロドラッグ
CN106999462B (zh) 包含选择性s1p1受体激动剂的药物组合物
KR20010052721A (ko) 급성 천식 질환의 예방 또는 치료를 위한 포르모테롤 및부데소니드를 포함하는 조성물의 용도
CN1277553A (zh) 血管生成促进剂和血管生成增效剂
KR20190116320A (ko) 오래 지속되는 자가 포식 유도를 위한 동위 원소 강화 암브록솔
CN1646527A (zh) 包含β模拟剂(BETAMIMETICS)及新颖抗胆碱酯酶的药物
CN1053337C (zh) 自身免疫性疾病治疗药
CN1400909A (zh) 药用组合物
CN1382042A (zh) 用rar选择性视黄醛衍生物拮抗剂治疗肺气肿
CN1691946A (zh) 他克莫司(FK506)衍生物联合β2－激动剂用于治疗哮喘的用途
CN1537004A (zh) 用于经鼻给药的含有咪唑并三嗪酮化合物的组合物
CN1133424C (zh) 口服给药的雷怕霉素制剂
CN1610548A (zh) 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用
CN1111407C (zh) 抗癌组合物
CN1210064C (zh) 治疗球虫病的组合物
CN1433317A (zh) 免疫抑制剂用于增强脂肽抗真菌活性的用途
CN1267097C (zh) 噻唑类衍生物在制备可用于治疗慢性阻塞性肺病的药物中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTELLAS PHARMA INC.

Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD.

Effective date: 20060414

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060414

Address after: Tokyo, Japan

Applicant after: Yamanouchi Pharma Co., Ltd.

Address before: Osaka City, Osaka of Japan

Applicant before: Fujisawa Pharmaceutical Co., Ltd.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication